On Friday, Shares of Pfizer Inc. (NYSE:PFE), gained 0.90% to $34.75.
Pfizer, declared study results demonstrating palbociclib in combination with fulvestrant was superior to treatment with a standard of care, fulvestrant, by significantly extending progression-free survival (PFS) in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer whose disease has progressed during or after endocrine therapy (HR 0.42, median PFS, 9.2 vs. 3.8 months, in their respective arms, p<0.000001). Results from the Phase 3 PALOMA-3 study will be featured recently in a press briefing during the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) and will be presented as a late-breaker on Monday, June 1 at 8:00 a.m. CDT (Abstract #LBA502). The results will also be simultaneously published online by The New England Journal of Medicine. The Principal Investigator for the study, Nicholas C. Turner, MD, PhD, consultant medical oncologist at The Royal Marsden and Institute of Cancer Research in London, United Kingdom, will present these data.
PALOMA-3 (also known as Study A5481023) is a multi-center trial with more than 140 global sites participating and 521 patients enrolled. The study is a randomized (2:1), double-blind Phase 3 study designed to assess the PFS of palbociclib (125 mg once daily orally for three out of four weeks in each cycle) in combination with fulvestrant (500 mg intramuscularly on days 1 and 15 of cycle 1, and then on day 1 of each subsequent 28 day cycle) as compared to fulvestrant plus placebo in pre/perimenopausal and postmenopausal women with HR+, HER2- metastatic breast cancer whose disease has progressed during or after endocrine therapy. Pre/perimenopausal women also received ovarian suppression (goserelin). PFS is defined as time from randomization to time of disease progression or death from any cause.
As formerly revealed, the PALOMA-3 study met its primary endpoint of PFS at the interim analysis and was stopped early in April 2015 due to efficacy based on an assessment by an independent Data Monitoring Committee (DMC). Benefit from palbociclib was also demonstrated across all pre-specified subgroups, counting both pre/perimenopausal and postmenopausal patients. At the time of the PFS analysis, overall survival (OS) data was immature.
Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. The company operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments. The GIP segment develops, registers, and commercializes medicines for various therapeutic areas, counting inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases, and women’s/men’s health.
Shares of The Dow Chemical Company (NYSE:DOW), inclined 0.97% to $52.07, during its last trading session. On Friday, the shares floated in a range of $51.26 - $52.23. The company exchanged hands with 10,730,277 shares as compared to its average daily volume of 7,562,840 shares. The company has market capitalization of 60.03B.
The Dow Chemical Company manufactures and supplies products that are used primarily as raw materials in the manufacture of customer products and services worldwide.
At the end of Friday’s trade, Shares of Xilinx Inc. (NASDAQ:XLNX), lost -0.79% to $47.42.
Xilinx, declared that it has collaborated with TSMC on the 7nm process and 3D IC technology for its next generation of All Programmable FPGAs, MPSoCs, and 3D ICs. The technology represents the fourth successive generation where the two companies have worked together on advanced process and CoWoS 3D stacking technology, and will become TSMC’s fourth generation of FinFET technology. The partnership will provide Xilinx a multi-node scaling advantage and build on its outstanding product, execution, and market success at 28nm, 20nm, and 16nm nodes.
Xilinx plans to introduce new 7nm products in 2017.
Xilinx, Inc. designs and develops programmable devices and associated technologies worldwide. Its programmable devices comprise integrated circuits (ICs) in the form of programmable logic devices (PLDs), such as programmable system on chips, and three dimensional ICs; software design tools to program the PLDs; targeted reference designs; printed circuit boards; and intellectual property (IP), which comprises of Xilinx and various third-party verification and IP cores.
Finally, Public Service Enterprise Group Inc. (NYSE:PEG), ended its last trade with -0.98% loss, and closed at $42.63.
While National Electrical Safety Month may be drawing to a close, PSEG Long Island reminds its customers that being safe around electric lines and equipment is a year-round commitment. As part of its promise to assist even its youngest customers be safe around electricity, PSEG Long Island is seeking summer schools and camps interested in its Electric Safety Education Program. The program shares presentations and tips for children on how electricity works and how to use it wisely and safely.
The electricity PSEG Long Island delivers is essential to modern life, yet its power can sometimes be taken for granted. In the presentations, the Electric Safety Education team creates scenarios to teach children what to do in dangerous situations and what precautions should be taken to avoid getting hurt.
In addition to its program for school age children, the PSEG Foundation partnered with Sesame Workshop to develop the Let’s Get Ready and Here for Each Other apps to assist prepare preschool children for emergencies.
Public Service Enterprise Group Incorporated, through its auxiliaries, operates as an energy company primarily in the northeastern and Mid Atlantic United States. The company operates nuclear, coal, gas, oil-fired, and renewable generation facilities with a generation capacity of about 13,146 megawatts.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
